Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Recruiting now

Conditions studied: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR

In brief

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Key facts

Study ID

NCT06465810

Run by

AstraZeneca

People needed

1850

Starts

2024-06-25

Expected to finish

2031-12-29

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient willing and able to provide written informed consent to participate in the study
• Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
• Aged ≥18 years at the time of signing the informed consent
• Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)

You may not qualify if…

• Concurrent participation in any interventional trial for ATTR amyloidosis
• Involvement in the planning and/or conduct of the current study
• Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
• Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Where it is running

• Research Site — La Jolla, California, United States (enrolling)
• Research Site — San Francisco, California, United States (enrolling)
• Research Site — San Francisco, California, United States (enrolling)
• Research Site — Los Angeles, California, United States (enrolling)
• Research Site — Washington D.C., District of Columbia, United States (enrolling)
• Research Site — Chicago, Illinois, United States (enrolling)
• Research Site — Indianapolis, Indiana, United States (enrolling)
• Research Site — Boston, Massachusetts, United States (enrolling)
• Research Site — New Haven, Connecticut, United States (enrolling)
• Research Site — Boston, Massachusetts, United States (enrolling)
• Research Site — Rochester, Minnesota, United States (enrolling)
• Research Site — Kansas City, Missouri, United States (enrolling)
• Research Site — St Louis, Missouri, United States (enrolling)
• Research Site — New Brunswick, New Jersey, United States (enrolling)
• Research Site — Manhasset, New York, United States (enrolling)
• Research Site — New York, New York, United States (enrolling)
• Research Site — New York, New York, United States (enrolling)
• Research Site — Durham, North Carolina, United States (enrolling)
• Research Site — Portland, Oregon, United States (enrolling)
• Research Site — Danville, Pennsylvania, United States (enrolling)
• Research Site — Philadelphia, Pennsylvania, United States (enrolling)
• Research Site — Philadelphia, Pennsylvania, United States (enrolling)
• Research Site — Greenville, South Carolina, United States (enrolling)
• Research Site — Germantown, Tennessee, United States (enrolling)
• Research Site — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.